Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.

Gulhati P, Prakash L, Katz MHG, Wang X, Javle M, Shroff R, Fogelman D, Lee JE, Tzeng CD, Lee JH, Weston B, Tamm E, Bhosale P, Koay EJ, Maitra A, Wang H, Wolff RA, Varadhachary GR.

Ann Surg Oncol. 2019 Feb;26(2):619-627. doi: 10.1245/s10434-018-6807-9. Epub 2018 Oct 15.

PMID:
30324485
2.

Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.

Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ.

Oncologist. 2018 Mar;23(3):277-e26. doi: 10.1634/theoncologist.2017-0568. Epub 2017 Dec 19.

3.

Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.

Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ.

Cancer. 2017 May 15;123(6):1011-1017. doi: 10.1002/cncr.30445. Epub 2016 Nov 14.

4.

Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors.

Kim JT, Li J, Jang ER, Gulhati P, Rychahou PG, Napier DL, Wang C, Weiss HL, Lee EY, Anthony L, Townsend CM Jr, Liu C, Evers BM.

Carcinogenesis. 2013 May;34(5):953-61. doi: 10.1093/carcin/bgt018. Epub 2013 Jan 25.

5.

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.

Gulhati P, Zaytseva YY, Valentino JD, Stevens PD, Kim JT, Sasazuki T, Shirasawa S, Lee EY, Weiss HL, Dong J, Gao T, Evers BM.

Carcinogenesis. 2012 Sep;33(9):1782-90. doi: 10.1093/carcin/bgs203. Epub 2012 Jun 13.

6.

The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer.

Li X, Stevens PD, Yang H, Gulhati P, Wang W, Evers BM, Gao T.

Oncogene. 2013 Jan 24;32(4):471-8. doi: 10.1038/onc.2012.66. Epub 2012 Mar 5.

7.

Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.

Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O'Connor K, Morris AJ, Sunkara M, Weiss HL, Lee EY, Evers BM.

Cancer Res. 2012 Mar 15;72(6):1504-17. doi: 10.1158/0008-5472.CAN-11-4057. Epub 2012 Jan 19.

8.

mTOR inhibitors in cancer therapy.

Zaytseva YY, Valentino JD, Gulhati P, Evers BM.

Cancer Lett. 2012 Jun 1;319(1):1-7. doi: 10.1016/j.canlet.2012.01.005. Epub 2012 Jan 17. Review.

PMID:
22261336
9.

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.

Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T, Evers BM.

Cancer Res. 2011 May 1;71(9):3246-56. doi: 10.1158/0008-5472.CAN-10-4058. Epub 2011 Mar 23.

10.

Characterization of promoter elements regulating the expression of the human neurotensin/neuromedin N gene.

Wang X, Gulhati P, Li J, Dobner PR, Weiss H, Townsend CM Jr, Evers BM.

J Biol Chem. 2011 Jan 7;286(1):542-54. doi: 10.1074/jbc.M110.145664. Epub 2010 Oct 28.

11.

Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.

Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL, Evers BM.

J Am Coll Surg. 2010 May;210(5):767-76, 776-8. doi: 10.1016/j.jamcollsurg.2009.12.008.

12.

Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.

Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, Lee EY, Silva SR, Bowen KA, Gao T, Evers BM.

Clin Cancer Res. 2009 Dec 1;15(23):7207-16. doi: 10.1158/1078-0432.CCR-09-1249. Epub 2009 Nov 24.

13.

Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling.

Johnson SM, Gulhati P, Arrieta I, Wang X, Uchida T, Gao T, Evers BM.

Anticancer Res. 2009 Aug;29(8):3185-90. Erratum in: Anticancer Res. 2009 Oct;29(10):4315.

14.

An analysis of trends and growth factor receptor expression of GI carcinoid tumors.

Bowen KA, Silva SR, Johnson JN, Doan HQ, Jackson LN, Gulhati P, Qiu S, Riall TS, Evers BM.

J Gastrointest Surg. 2009 Oct;13(10):1773-80. doi: 10.1007/s11605-009-0958-8. Epub 2009 Jul 7.

15.

Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.

Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, Chung DH, Evers BM.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20315-20. doi: 10.1073/pnas.0810715105. Epub 2008 Dec 15.

Supplemental Content

Loading ...
Support Center